IN8bio, Inc. Files 8-K with Financials
Ticker: INAB · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, exhibits
TL;DR
IN8BIO filed an 8-K on 3/3/25 for financials & exhibits.
AI Summary
On March 3, 2025, IN8bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. The company, formerly known as Incysus Therapeutics, Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides updated financial information and exhibits for IN8bio, Inc., which is important for investors to assess the company's current financial health and operational status.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, not indicating any significant new risks or events.
Key Numbers
- 001-39692 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-5462585 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IN8bio, Inc. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former company name
- March 3, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive office city
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report Other Events and to provide Financial Statements and Exhibits.
When was this report filed?
This report was filed on March 3, 2025.
What was IN8bio, Inc.'s former company name?
IN8bio, Inc.'s former company name was Incysus Therapeutics, Inc.
In which state is IN8bio, Inc. incorporated?
IN8bio, Inc. is incorporated in Delaware.
What is the address of IN8bio, Inc.'s principal executive offices?
The address of IN8bio, Inc.'s principal executive offices is 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding IN8BIO, INC. (INAB).